About Us

Headquartered in Switzerland with subsidiaries in Hungary and India, Extrovis is a global pharmaceutical company dedicated to creating and delivering products that make human lives better, simpler, and more convenient. We are on a mission every day to improve the quality of health and living.

We have a clear focus on the development and manufacturing of niche and differentiated finished-dose pharmaceutical products.

Our Indian entity employs a team of 60 scientists and researchers dedicated to developing our complex APIs and finished dosage form pharmaceutical products.

To support our ambitious plans for entering the European markets with our products, Extrovis has recently established its presence in Hungary and employs a team of professionals at its multipurpose entity in the supply chain (including primary and secondary packaging), regulatory, pharmacovigilance and customer service. These teams are planned to service also other regulated markets in the future.





Our Portfolio

Leveraged between all major geographies, our portfolio comprises three key types of products

- Niche or below-the-radar generic products.
- Products with formulation improvements including lyo-to-liquid conversion
- Redesigned products delivering efficient modern-day solutions that help improve patient safety and convenience, mostly as drug-device combinations

What We Do

Our research focuses on the development of new and differentiated FDFs and APIs to keep us at the forefront of innovation in pharmaceutical process and intellectual property development. Extrovis concurrently maintains strategy and development teams in India, the EU and US.

Each of our teams champion special areas of expertise, with the full support and collaboration of all our other divisions, particularly by our experienced Development Quality Assurance and Analytical Teams.

Our Scientific and Technical teams maintain a fascinating mindset of passion, exceptional professionalism matched by speed, flexibility and a desire for a value creation for stakeholders and customers worldwide.

Finished Dosage Forms

The Key Pillars Of Our Balanced FDF Portfolio Strategy Are

Niche/under-the-radar opportunities and segments that are less visible without in-depth market research

Innovation-driven portfolio focusing on formulation improvements offering increased bioavailability, patient compliance and convenience, overall cost efficiency of therapy and/ or medical waste management.

Our Scientific and Technical teams maintain a fascinating mindset of passion and exceptional professionalism matched by speed, flexibility, and a desire for value creation for stakeholders and customers worldwide.



FDF Research And Development

Extrovis' R&D team applies a cross-functional approach utilizing expertise from multiple disciplines such as analytical, engineering, quality assurance, clinical, and regulatory affairs.

Our state-of-the-art development center with a team of over 60 scientists has a proven track record of taking highly complex products and unique technologies from a portfolio concept to commercialization.

Regulatory Affairs

Extrovis' regulatory team is capable of developing regulatory strategies and managing dossier submissions and compliance across the globe. Our area of activity now includes, besides the US and EU also China, Brazil, and other global markets.

Backward Integration Of Key Projects

In-house development of critical or low availability APIs to ensure long term cost competitiveness and supply chain continuity.

How We Do It

Global Presence

Extrovis currently maintains strategy and development teams in India, the EU and US. Our area of activity also includes the US, China, Brazil and we plan to expand across other global markets.

Research & Development Centres

Our research centres operate at the heart of new and differentiated FDFs, APIs and Intermediates. To keep us at the forefront of innovation in pharmaceutical process and intellectual property development, Extrovis concurrently maintains strategy and development teams in India, the EU and US.

Each of our teams champion special areas of expertise, with the full support and collaboration of all our other divisions, particularly our experienced Development Quality Assurance and Analytical Teams.

Our scientific and technical teams maintain a fascinating mindset of passion, and exceptional professionalism, matched by speed, flexibility, and a desire for value creation for stakeholders and customers worldwide.

Supply Chain Hub

Extrovis EU, based in Hungary, has been set up to function as a global supply chain and customer care hub for the group. We successively build capabilities locally for the following key activities:

- EU importation, re-testing and release
- Primary & secondary packaging
- Late stage customization of various dosage forms for European and other markets
- Managing regulatory and pharmacovigilance procedures
- Supply chain co-ordination and customer care

With a collective experience of more than 50 years in Europe, we aim to address the supply chain complexity of European generic pharmaceutical market by reconciling high volume, efficient manufacturing with medium to small volume order demand.

We expect this setup to become fully operational by Q4, 2022.

GMP Manufacturing

API GMP Manufacturing

Extrovis' state-of-the-art manufacturing and R&D facilities, as well as those seamlessly integrated by our partnership network in the EU and India, all comply with the highest international quality standards with accreditations from the USFDA, PMDA, EU and other global regulatory bodies.

Where We Manufacture

APIs: Through strategic manufacturing partnerships in India and Europe.

Regulatory Approvals: API manufacturing sites approved by USFDA, EU Authorities and PMDA Japan.

FDF GMP Manufacturing

We choose GMP manufacturing partners best positioned to produce our diverse range of dosage forms including, vials, cartridges, pre-filled syringes, and bags besides oral solid forms. Most of our contract manufacturing partners have capacity sharing arrangement with Extrovis to ensure long term supply continuity. Extrovis' Global Quality Management System oversees the entire manufacturing process, while our alliance management function gets involved with our partners every step of the way.

Contact Us

Our Contact

Email Address

corporate@extrovis.com

Call Us

+41 41 740 1120

Address

Extrovis AG, Global Corporate Office
Bahnhof-Park 4, Baar
6340, Switzerland